


A Quick Look at Using Prevnar 13™ (PCV13)

Pneumococcal Conjugate Vaccine for Children through Age 18 Years

<p>Indications for Use of PCV13 and Schedule</p> <p><u>Routine Schedule</u></p> <ul style="list-style-type: none"> · 4 doses: a 3-dose primary series at 2, 4, 6 months and a booster dose at 12-15 months <ul style="list-style-type: none"> - Children who do not start or continue the series on time may need less doses to complete the series - Children with an incomplete schedule who are: <ul style="list-style-type: none"> · Healthy & ages 24 through 59 months receive 1 dose · High risk & ages 2 through 18 years receive 1-2 doses based on previous history (see below) <p><u>Minimum Intervals</u></p> <ul style="list-style-type: none"> · 4 weeks between doses given <u>before</u> age 12 months · 8 weeks between doses given <u>at/after</u> age 12 months 	<p>Vaccine Administration</p> <p>Intramuscular (IM) injection in the anteriolateral thigh or deltoid of the arm</p> <ul style="list-style-type: none"> · 1 inch needle; 22-25 gauge · Professional judgment is appropriate when selecting needle length and site · Can be given with other vaccines, at the same visit (use separate sites; space at least 1 inch apart) <hr/> <p>Storage and Handling</p> <ul style="list-style-type: none"> · Store in the refrigerator between 35°-46°F (2°-8°C) · Do NOT freeze · Keep in the original box <div style="text-align: right; margin-top: 10px;">  </div>
--	--

Contraindications

- An anaphylactic reaction to a prior dose of Pneumococcal Conjugate Vaccine (PCV7 or PCV13) or any diphtheria-toxoid containing vaccine **or** an anaphylactic reaction to a component of PCV13 vaccine

Precautions

- Moderate to severe acute illness

Transitioning to PCV13 from PCV7¹

- **Children through age 59 months** that have completed a PCV7 series and have not received a dose of PCV13:
 - Give one dose of PCV13
 - Minimum interval of 8 weeks since the last dose of any pneumococcal vaccine (PCV13 or PPSV23)

▪ **High Risk Children**

- **Ages 24 through 71 months²**
 - If incomplete schedule of 2 or less doses, give 2 doses of PCV13
 - If incomplete schedule of 3 doses, give 1 dose of PCV13
 - Use a minimum interval of 8 weeks since the last dose of PCV7, PCV13 or PPSV23
- **Ages 6 through 18 years³**
 - Give a single supplemental dose of PCV13 if no previous dose of PCV13, regardless of previous history of receiving PCV7 or PPSV23 vaccine.
 - Use a minimum interval of 8 weeks since the last dose of PCV7 or PPSV23

¹ Refer to “Recommended Schedule for Administering Doses of PCV13” for more details (www.michigan.gov/immunize)

² High risk children ages 24-71 months include: a) immunocompetent (chronic lung or heart disease, diabetes, cochlear implant, cerebrospinal fluid (CSF) leak, b) immunocompromised (HIV, chronic renal or nephrotic syndrome, chemotherapy or radiation therapy for neoplasms, leukemia, lymphoma, solid organ transplant), c) functional or anatomic asplenia (no spleen, sickle cell disease)

³ High risk children ages 6-18 years include: functional or anatomic asplenia, including sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant or CSF leak

Further Points

- PCV7 = Pneumococcal Conjugate Vaccine, Prevnar™ PPSV23 = Pneumococcal Polysaccharide Vaccine, Pneumovax®
- PCV13 contains an additional 6 serotypes against *Streptococcus pneumoniae*, including 19a, the most common pneumococcal serotype and often resistant to antibiotics.
- Use the current VIS for PCV or the Multi-Vaccine VIS that includes information about MI Care Improvement Registry (MCIR)
- VISs are available at www.michigan.gov/immunize or at your local health department.
- Document as “PCV13” (Prevnar 13) in MCIR and PCV13 on the vaccine administration record & immunization record card

Refer to “Prevention of Pneumococcal Disease among Infants & Children, Use of PCV13 & PPSV23” MMWR December 10, 2010”, ACIP VFC “Vaccines to Prevent Pneumococcal Disease” February 2013 at www.cdc.gov/vaccines. Updates of this Quick Look handout are posted at: www.michigan.gov/immunize. Publicly-purchased PCV13 can be administered to eligible children 6 weeks through 18 years of age through the Vaccines for Children (VFC) Program in private providers’ offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information.



Recommended Schedule for Administering Doses of PCV13¹ (Pneumococcal Conjugate Vaccine for Children aged 2 Months through 18 Years)

Age at this visit	Vaccination History: Total number of PCV7 and/or PCV13 doses previously received	Recommended PCV13 Dose(s) ²
2-6 months	0 doses	3 doses, 8 weeks apart; 4 th dose at age 12-15 months
	1 dose	2 doses, 8 weeks apart; 4 th dose at age 12-15 months
	2 doses	1 dose, 8 weeks after the last dose; 4 th dose at age 12-15 months
7-11 months	0 doses	2 doses, 8 weeks apart 3 rd dose at 12-15 months
	1 or 2 doses before age 7 months	1 dose at age 7-11 months; 2 nd dose at age 12-15 months (at least 8 weeks later)
12-23 months	0 doses	2 doses, at least 8 weeks apart
	1 dose before age 12 months	2 doses, at least 8 weeks apart
	1 dose at/after age 12 months	1 dose, at least 8 weeks after the last dose ³
	2 or 3 doses before age 12 months	1 dose, at least 8 weeks after the last dose ³
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 dose, at least 8 weeks after the last dose ³
Healthy Children 24-59 months	Any incomplete schedule	1 dose, at least 8 weeks after the last dose ³
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 dose, at least 8 weeks after the last dose ⁴
High Risk Children 24-71 months⁵	Any incomplete series of 2 <u>or</u> less doses	2 doses, one at least 8 weeks after the last dose & another dose at least 8 weeks later
	Any incomplete series of 3 doses	1 dose, at least 8 weeks after the last dose
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 dose, at least 8 weeks after the last dose ⁴
High Risk Children 6-18 years⁶	Whether or not any previous doses of PCV7 or PPSV23 were given	If no previous dose of PCV13, give one dose, at least 8 weeks after any previous doses of PCV7 or PPSV23

¹ Pneumococcal Conjugate Vaccine 13; Prevnar 13™, Wyeth (a subsidiary of Pfizer)

² Minimum intervals between doses is 8 weeks except for children vaccinated at ages less than 12 months, then the minimum interval is 4 weeks

³ No additional PCV13 doses are indicated for children ages 12 through 23 months who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.

⁴ A single supplemental dose of PCV13 given at least 8 weeks after the last dose of PCV7 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule (fully vaccinated with PCV7). For children who have underlying medical conditions, a supplemental dose is recommended through 71 months of age.

⁵ Children ages 24-71 months in one of the following risk groups

- Immunocompetent: chronic heart and lung disease, diabetes, cerebrospinal fluid leaks, cochlear implants
- Immunocompromised: HIV, chronic renal failure or nephrotic syndrome, or diseases associated with immunosuppressive chemotherapy or radiation therapy including neoplasms, leukemia, lymphomas or solid organ transplant.
- Sickle cell disease and other hemoglobinopathies; congenital or acquired asplenia or splenic dysfunction.

⁶ For children ages 6 through 18 years with functional or anatomic asplenia, including sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant or CSF leak